MILCICLIB MALEATE

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H32N8O.C4H4O4
Molecular Weight	576.6467
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)\C=C/C(O)=O.CNC(=O)C1=NN(C)C2=C1C(C)(C)CC3=CN=C(NC4=CC=C(C=C4)N5CCN(C)CC5)N=C23

InChI

InChIKey=DGVCEXQFNYYRQI-BTJKTKAUSA-N

InChI=1S/C25H32N8O.C4H4O4/c1-25(2)14-16-15-27-24(29-20(16)22-19(25)21(23(34)26-3)30-32(22)5)28-17-6-8-18(9-7-17)33-12-10-31(4)11-13-33;5-3(6)1-2-4(7)8/h6-9,15H,10-14H2,1-5H3,(H,26,34)(H,27,28,29);1-2H,(H,5,6)(H,7,8)/b;2-1-

HIDE SMILES / InChI

Molecular Formula	C4H4O4
Molecular Weight	116.0722
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Molecular Formula	C25H32N8O
Molecular Weight	460.5746
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=660138
Curator's Comment: description was created based on several sources, including: http://adisinsight.springer.com/drugs/800026196 | http://www.tizianalifesciences.com/Thymic_Liver_Cancer.html | http://meetinglibrary.asco.org/content/131226-144 | https://www.ncbi.nlm.nih.gov/pubmed/22160853

An orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activity. CDK2/TRKA inhibitor PHA-848125 AC potently inhibits cyclin-dependent kinase 2 (CDK2) and exhibits activity against other CDKs including CDK1 and CDK4, in addition to TRKA. Inhibition of these kinases may result in cell cycle arrest and apoptosis of tumor cells that express these kinases. Milciclib is currently in phase II clinical trials for thymic carcinoma, glioma and liver cancer. The most common adverse events are nausea and asthenia, vomiting, myasthenic syndrome, dehydration, hypophosphatemia, cytolytic hepatitis and plantar fasciitis.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
CDK2/Cyclin A 7 Target ID: CHEMBL3038469 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19603809	Inhibitor 8504	45.0 nM [IC50]
Cyclin-dependent kinase 4/cyclin D1 11 Target ID: CHEMBL1907601 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19603809	Inhibitor 8504	160.0 nM [IC50]
Cyclin-dependent kinase 2/cyclin E 10 Target ID: CHEMBL2094126 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19603809	Inhibitor 8504	363.0 nM [IC50]
Cyclin-dependent kinase 5/CDK5 activator 1 8 Target ID: CHEMBL1907600 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19603809	Inhibitor 8504	265.0 nM [IC50]
Cyclin-dependent kinase 1/cyclin B 5 Target ID: CHEMBL2094127 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19603809	Inhibitor 8504	398.0 nM [IC50]
Cyclin-dependent kinase 7/ cyclin H 7 Target ID: CHEMBL2111288 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19603809	Inhibitor 8504	150.0 nM [IC50]
Nerve growth factor receptor Trk-A 15 Target ID: CHEMBL2815 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19603809	Inhibitor 8504	53.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Thymic carcinoma 2 Sources: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2013/07/WC500145399.pdf	Primary	Phase II 1147	Unknown Approved Use Unknown
Glioma 25 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23347136	Primary	Phase II 1147	Unknown Approved Use Unknown
Hepatocellular carcinoma 83 Sources: http://www.tizianalifesciences.com/Thymic_Liver_Cancer.html	Primary	Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
1.47 μM OTHER GOV https://clinicaltrials.gov/ProvidedDocs/91/NCT01301391/Prot_000.pdf	150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MILCICLIB plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED
1.5 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/22160853	150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MILCICLIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
25.3 μM × h OTHER GOV https://clinicaltrials.gov/ProvidedDocs/91/NCT01301391/Prot_000.pdf	150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MILCICLIB plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED
25 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/22160853	150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MILCICLIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
33.3 h OTHER GOV https://clinicaltrials.gov/ProvidedDocs/91/NCT01301391/Prot_000.pdf	150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MILCICLIB plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED
33.1 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/22160853	150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MILCICLIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
16% OTHER GOV https://clinicaltrials.gov/ProvidedDocs/91/NCT01301391/Prot_000.pdf	150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MILCICLIB plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED

Sourcing

Vendor/Aggregator	ID	URL
AChemBlock	A-627	http://www.achemblock.com/catalogsearch/result/?q=A-627
AK Scientific	Y0330	https://aksci.com/item_detail.php?cat=Y0330
Angene	AGN-PC-0UGSGY	http://www.angenechemical.com/productshow/AGN-PC-0UGSGY.html
AOBIOUS INC	AOB87199	http://aobious.com/aobious/search?search_query=AOB87199
ApexBio Technology	A8501	https://www.apexbt.com/catalogsearch/result/?q=A8501
BLD Pharm	BD211339	http://www.bldpharm.com/search/Search.html?keyword=BD211339
BOC Sciences	802539-81-7	http://www.bocsci.com/description.asp?cas=802539-81-7
Chem Scene	CS-0579	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0579
ChemShuttle	111897	https://www.chemshuttle.com/catalogsearch/result/?q=111897
Debye Scientific	DB-075668	https://www.debyesci.com/index.php?id=product&ext[cno]=DB-075668
eMolecules	43366920	https://orderbb.emolecules.com/search/#?query=43366920
eNovation Chemicals	D372562	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D372562&searchbtn.x=0&searchbtn.y=0
Excenen	EX-A2135	http://www.excenen.com/searchresultlist.php?id=EX-A2135
KeyOrganics	AS-56203	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-56203
Lab Seeker	SC-85447	http://www.labseeker.com/search.php?keywords=SC-85447&category=0
LabSeeker	SC-85447	http://www.labseeker.com/search.php?keywords=SC-85447&category=0
Matrix Scientific	147239	http://www.matrixscientific.com/147239.html
mcule	MCULE-5534623468	https://mcule.com/MCULE-5534623468/
MedChem Express	HY-10424	https://www.medchemexpress.com/search.html?q=HY-10424&ft=&fa=&fp=
Molnova	M16004	https://www.molnova.com/en/serch-list.html?keywords=M16004
MolPort	MolPort-021-804-994	https://www.molport.com/shop/molecule-link/MolPort-021-804-994
MuseChem	I004922	https://www.musechem.com/product/I004922.html
ShangHai Biochempartner	BCP01918	http://www.biochempartner.com/search_BCP01918
Toronto Research Chemicals	P294490	https://www.trc-canada.com/product-detail/?CatNum=P294490

PubMed

Title	Date	PubMed
Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy.	2010-08	20682657
The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound.	2010-05	20026273
Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging.	2010-03	20197397
Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.	2009-08-27	19603809

Patents

Sample Use Guides

In Vivo Use Guide

150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.

Route of Administration: Oral

In Vitro Use Guide

The effects of compound Milciclib on the cell cycle progression and DNA synthesis were analyzed using flow cytometry analysis and BrdU incorporation, respectively, on A2780 ovarian carcinoma cells in exponential growth in the presence or absence of compound, for 24 h at 1 μM. At this concentration, the compound was able to show a clear reduction of S phase population, which was associated with an increase of G1 population as expected for a CDK2/cyclin A inhibitor.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:22:14 GMT 2025` Edited by `admin` on `Mon Mar 31 18:22:14 GMT 2025`
Record UNII	82W826FL6S
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PHA-848125AC

Preferred Name

English

MILCICLIB MALEATE

Common Name

English

1H-PYRAZOLO(4,3-H)QUINAZOLINE-3-CARBOXAMIDE, 4,5-DIHYDRO-N,1,4,4-TETRAMETHYL-8-((4-(4-METHYL-1-PIPERAZINYL)PHENYL)AMINO)-, (2Z)-2-BUTENEDIOATE (1:1)

Systematic Name

English

Milciclib maleate [WHO-DD]

Common Name

English

Classification Tree Code System Code

EU-Orphan Drug

EU/3/12/1059